225 related articles for article (PubMed ID: 28105368)
1. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
[No Abstract] [Full Text] [Related]
3. Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition.
Sodji Q; Klein K; Sravan K; Parikh J
J Immunother Cancer; 2017 Aug; 5(1):62. PubMed ID: 28807004
[TBL] [Abstract][Full Text] [Related]
4. Renal Medullary Carcinoma and Sickle Cell Trait: A Push for Early Diagnosis and Intervention Report of Two Cases.
Carter SA; Walker AN
J Natl Med Assoc; 2017 Spring; 109(1):63-65. PubMed ID: 28259220
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.
Lipkin JS; Rizvi SM; Gatalica Z; Sarwani NE; Holder SL; Kaag M; Drabick JJ; Joshi M
Cancer Biol Ther; 2015; 16(1):28-33. PubMed ID: 25692619
[TBL] [Abstract][Full Text] [Related]
6. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
[TBL] [Abstract][Full Text] [Related]
7. Cystic presentation of a renal medullary carcinoma in a young woman.
Levi Sandri GB; Spoletini G; Lai Q; Mennini G; Rossi M
Urologia; 2015; 82(2):124-6. PubMed ID: 25451881
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series.
Ryan A; Tawagi K; VanderVeen N; Matrana M; Vasquez R
Clin Genitourin Cancer; 2021 Dec; 19(6):e395-e400. PubMed ID: 34565708
[TBL] [Abstract][Full Text] [Related]
9. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of renal medullary carcinoma: potential clinical relevance.
Yang XJ; Sugimura J; Tretiakova MS; Furge K; Zagaja G; Sokoloff M; Pins M; Bergan R; Grignon DJ; Stadler WM; Vogelzang NJ; Teh BT
Cancer; 2004 Mar; 100(5):976-85. PubMed ID: 14983493
[TBL] [Abstract][Full Text] [Related]
11. Renal Medullary Carcinoma: a Report of the Current Literature.
Blas L; Roberti J; Petroni J; Reniero L; Cicora F
Curr Urol Rep; 2019 Jan; 20(1):4. PubMed ID: 30656488
[TBL] [Abstract][Full Text] [Related]
12. Renal medullary carcinoma and ABL gene amplification.
Simpson L; He X; Pins M; Huang X; Campbell SC; Yang XJ; Perlman EJ; Bergan RC
J Urol; 2005 Jun; 173(6):1883-8. PubMed ID: 15879768
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Renal Medullary Carcinoma.
Su Y; Hong AL
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806102
[TBL] [Abstract][Full Text] [Related]
14. Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy.
Lattanzi M; Deng FM; Chiriboga LA; Femia AN; Meehan SA; Iyer G; Voss MH; Sundatova Y; Huang WC; Balar AV
J Immunother Cancer; 2018 Oct; 6(1):97. PubMed ID: 30285856
[TBL] [Abstract][Full Text] [Related]
15. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
[TBL] [Abstract][Full Text] [Related]
16. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
[TBL] [Abstract][Full Text] [Related]
17. Renal medullary carcinoma: A national analysis of 159 patients.
Ezekian B; Englum B; Gilmore BF; Nag UP; Kim J; Leraas HJ; Routh JC; Rice HE; Tracy ET
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28485059
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.
Yasuoka S; Hamasaki T; Kuribayashi E; Nagasawa M; Kawaguchi T; Nagashima Y; Kondo Y
Medicine (Baltimore); 2018 Nov; 97(45):e13173. PubMed ID: 30407350
[TBL] [Abstract][Full Text] [Related]
19. Renal medullary carcinoma in a white adolescent with sickle cell trait.
Daher P; Bourgi A; Riachy E; Khoury A; Rehayem C; Sader-Ghorra C
J Pediatr Hematol Oncol; 2014 Jul; 36(5):e285-9. PubMed ID: 24517963
[TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]